ProCyte Corp. will expand the European trials of its hair growthenhancer based on promising preliminary results from itsPhase II clinical study of Tricomin.
The European trial, which began in January and is scheduled toend in the first quarter of 1992, showed that more than 80percent of men had "significant normal hair growth" as early astwo months after starting twice-daily application of thepeptide-copper drug, according to Karen Hedine, spokeswomanfor the Kirkland, Wash., company.
ProCyte stock (NASDAQ:PRCY) jumped $1.25 on the news toclose at $8.75.
Preclinical testing of the compound in the United States isproceeding, as required for clinical trials in this country. -- RF
(c) 1997 American Health Consultants. All rights reserved.